- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | 24/7 Market News and NeOnc Technology: NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger | 2 | GlobeNewswire (USA) | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| Mi | 24/7 Market News and NeOnc Technology: NeOnc's Clinical Story Is Now the Main Event | 2 | GlobeNewswire (USA) | ||
| 20.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.08. | 24/7 Market News and NeOnc Technology: NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't | 1 | GlobeNewswire (USA) | ||
| 17.08. | 24/7 Market News and NeOnc Technology: NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results | 1 | GlobeNewswire (USA) | ||
| 13.08. | Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 | 431 | Newsfile | Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).... ► Artikel lesen | |
| 13.08. | 24/7 Market News and NeOnc Technology: The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech | 4 | GlobeNewswire (USA) | ||
| 12.08. | NeOnc reports phase 2a glioma trial meets primary endpoint | 4 | Investing.com | ||
| 12.08. | Investors Tape and NeOnc: Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer | 3 | GlobeNewswire (USA) | ||
| 12.08. | WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x | 404 | Newsfile | Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant... ► Artikel lesen | |
| 12.08. | Neonc Technologies: Aktie schießt nach überzeugenden Studiendaten in die Höhe | 7 | Investing.com Deutsch | ||
| 11.08. | WallStreet-PR: NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence | 499 | Newsfile | Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a... ► Artikel lesen | |
| 10.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.08. | NeOnc Technologies Holdings GAAP EPS of -$0.58 | 2 | Seeking Alpha | ||
| 10.08. | 24/7 Market News and NeOnc Technology: NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears | 1 | GlobeNewswire (USA) | ||
| 10.08. | NeOnc to present phase 2a NEO100 trial results on Tuesday | 2 | Investing.com | ||
| 10.08. | NeOnc Technologies Holdings, Inc.: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout | 652 | GlobeNewswire (Europe) | CALABASAS, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| 10.08. | NEONC TECHNOLOGIES HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 10.08. | NeOnc to present phase 2a trial results Wednesday | 2 | Investing.com | ||
| 27.07. | NeOnc beruft Nasim Shomali in den Verwaltungsrat | 2 | Investing.com Deutsch |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 9,845 | +1,56 % | Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline | MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,340 | 0,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| NOVOCURE | 15,365 | -0,19 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,050 | +0,56 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| ZAI LAB LTD ADR | 23,000 | +1,77 % | ZAI LAB (09688): 2026 INTERIM REPORT |
Das Unternehmen NEONC TECHNOLOGIES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+0,43 %) liegt der Kurs bei 4,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.